Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find ...

Moderna, based in Cambridge, will lay off 10% of its workforce and expects “to be fewer than 5,000 colleagues strong” by the ...

Moderna had said earlier this year it expects operating costs to be between $4.7 billion and $5 billion for 2027. MRNA stock, ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

Despite efforts to spare employees by scaling back R&D and reducing operating costs by roughly $1.5 billion over the next two ...

Moderna and Pfizer have plans to combine Covid-19 mRNA shots with those for flu and RSV in the years ahead if studies show that they're safe and effective.

Moderna announced that in the Phase 1/2 study, mRNA-1083 appeared to achieve antibody titers similar to or greater than both the licensed flu shot and the updated Covid-19 vaccine. The two-in-one ...

Moderna launched a clinical trial of an mRNA seasonal flu vaccine this summer, hoping to capture the same success as it did with its COVID-19 vaccine. Typically, seasonal flu shots are around 40 ...

Moderna started the first trial for its mRNA-based flu vaccine. The success of the mRNA COVID-19 vaccines accelerated work on other shots using the same approach.

Moderna said Wednesday that it has begun testing a flu vaccine as it seeks to expand the uses of the mRNA technology used in its COVID-19 vaccine. The first participants in an early-stage study ...